Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From WaveForm Diabetes
In an interview with Medtech Insight, Glooko CEO Russ Johannesson outlines the company’s growth opportunities, expansion plans beyond diabetes and financing plans.
Amazon's recent partnership with the Arcadia Group to supply blood glucose strips and meters under the new brand name Choice is another move by the retail giant to disrupt the health-care sector using the path of least resistance.
Innovative technology from companies such as Google offers the promise of new digital health options in the glucose monitoring market, while drastic reimbursement cuts affecting existing meters and supplies in the US are taking a noticeable toll on the major players already operating in the field. These competing factors have created a dichotomy characterized by opportunity on one side and uncertainly on the other, and that is forcing some competitors to re-think their business strategies.
Three years into the ACA, the biopharma industry takes stock of its near-term wins and losses as the law’s critical expanded insurance coverage takes effect beginning in 2014. Pharma still isn’t sure whether the increase in covered lives from the exchanges will boost prescription sales enough to offset the rebates, taxes, and fees it agreed to pay out, or what kind of patients constitute this new market.
- Digital Health
- Monitoring Equipment & Devices
In Vitro Diagnostics
- Glucose Testing
- Other Names / Subsidiaries
- AgaMatrix, Inc.
- AgaMatrix Europe, Ltd.
- AgaMatrix Holdings, LLC
- WaveForm Technologies Inc.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.